1. Home
  2. AAPG vs RARE Comparison

AAPG vs RARE Comparison

Compare AAPG & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ascentage Pharma Group International American Depository Shares

AAPG

Ascentage Pharma Group International American Depository Shares

N/A

Current Price

$13.05

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

N/A

Current Price

$17.34

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AAPG
RARE
Founded
2009
2010
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
2024
2013

Fundamental Metrics

Financial Performance
Metric
AAPG
RARE
Price
$13.05
$17.34
Analyst Decision
Strong Buy
Buy
Analyst Count
11
21
Target Price
★ $44.50
$24.80
AVG Volume (30 Days)
5.4K
★ 3.3M
Earning Date
08-19-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 7.31
EPS
★ N/A
N/A
Revenue
N/A
★ $673,000,000.00
Revenue This Year
$17.91
$12.70
Revenue Next Year
$111.96
$29.06
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 20.13
52 Week Low
$13.12
$12.73
52 Week High
$33.09
$39.89

Technical Indicators

Market Signals
Indicator
AAPG
RARE
Relative Strength Index (RSI) 34.59 58.03
Support Level N/A $14.11
Resistance Level $16.28 $17.67
Average True Range (ATR) 0.44 0.88
MACD -0.17 0.10
Stochastic Oscillator 0.00 86.86

Price Performance

Historical Comparison
AAPG
RARE

About AAPG Ascentage Pharma Group International American Depository Shares

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Share on Social Networks: